Know Cancer

or
forgot password

Observational Safety Data Analysis From Routine Follow-up in the EuroSIDA Study of Patients Treated With Raltegravir in a Five-Year Post Authorization Period


N/A
16 Years
N/A
Open (Enrolling)
Both
HIV-1 Infections

Thank you

Trial Information

Observational Safety Data Analysis From Routine Follow-up in the EuroSIDA Study of Patients Treated With Raltegravir in a Five-Year Post Authorization Period


Time Perspective: Retrospective and Prospective


Inclusion Criteria:



- Adults 16 years old and older with HIV-1

Exclusion Criteria:

- Subjects will be excluded if they have no prospective follow up

Type of Study:

Observational

Study Design:

Observational Model: Cohort

Outcome Measure:

Incidence of Malignancy (All malignancy collected)

Outcome Time Frame:

January 2000 - December 2014

Safety Issue:

Yes

Principal Investigator

Medical Monitor

Investigator Role:

Study Director

Investigator Affiliation:

Merck

Authority:

Denmark: Danish Medicines Agency

Study ID:

0518-058

NCT ID:

NCT01078233

Start Date:

May 2008

Completion Date:

December 2014

Related Keywords:

  • HIV-1 Infections
  • HIV
  • antiretroviral treatment
  • HIV Cohort
  • Treatment
  • HIV Infections

Name

Location